nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Pharyngeal oedema—Cyclosporine—focal segmental glomerulosclerosis	0.0605	0.0605	CcSEcCtD
Gadoversetamide—Urine abnormality—Cyclosporine—focal segmental glomerulosclerosis	0.0312	0.0312	CcSEcCtD
Gadoversetamide—Gastric ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.0298	0.0298	CcSEcCtD
Gadoversetamide—Urine analysis abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.0294	0.0294	CcSEcCtD
Gadoversetamide—Burning sensation—Cyclosporine—focal segmental glomerulosclerosis	0.0249	0.0249	CcSEcCtD
Gadoversetamide—Tongue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0238	0.0238	CcSEcCtD
Gadoversetamide—Feeling hot—Cyclosporine—focal segmental glomerulosclerosis	0.022	0.022	CcSEcCtD
Gadoversetamide—Breast pain—Cyclosporine—focal segmental glomerulosclerosis	0.0198	0.0198	CcSEcCtD
Gadoversetamide—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.0193	0.0193	CcSEcCtD
Gadoversetamide—Dysmenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.019	0.019	CcSEcCtD
Gadoversetamide—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.0188	0.0188	CcSEcCtD
Gadoversetamide—Creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.0182	0.0182	CcSEcCtD
Gadoversetamide—Eructation—Cyclosporine—focal segmental glomerulosclerosis	0.017	0.017	CcSEcCtD
Gadoversetamide—Cramps of lower extremities—Cyclosporine—focal segmental glomerulosclerosis	0.0159	0.0159	CcSEcCtD
Gadoversetamide—Disorientation—Cyclosporine—focal segmental glomerulosclerosis	0.014	0.014	CcSEcCtD
Gadoversetamide—Eye pain—Cyclosporine—focal segmental glomerulosclerosis	0.0139	0.0139	CcSEcCtD
Gadoversetamide—Injury—Cyclosporine—focal segmental glomerulosclerosis	0.0137	0.0137	CcSEcCtD
Gadoversetamide—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.0134	0.0134	CcSEcCtD
Gadoversetamide—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0129	0.0129	CcSEcCtD
Gadoversetamide—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.0118	0.0118	CcSEcCtD
Gadoversetamide—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.0115	0.0115	CcSEcCtD
Gadoversetamide—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.0111	0.0111	CcSEcCtD
Gadoversetamide—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.0109	0.0109	CcSEcCtD
Gadoversetamide—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.0107	0.0107	CcSEcCtD
Gadoversetamide—Sweating increased—Cyclosporine—focal segmental glomerulosclerosis	0.0106	0.0106	CcSEcCtD
Gadoversetamide—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.0101	0.0101	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00979	0.00979	CcSEcCtD
Gadoversetamide—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.00973	0.00973	CcSEcCtD
Gadoversetamide—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00941	0.00941	CcSEcCtD
Gadoversetamide—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00941	0.00941	CcSEcCtD
Gadoversetamide—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00923	0.00923	CcSEcCtD
Gadoversetamide—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00913	0.00913	CcSEcCtD
Gadoversetamide—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00908	0.00908	CcSEcCtD
Gadoversetamide—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.00873	0.00873	CcSEcCtD
Gadoversetamide—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.00871	0.00871	CcSEcCtD
Gadoversetamide—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00869	0.00869	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00864	0.00864	CcSEcCtD
Gadoversetamide—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.00862	0.00862	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00858	0.00858	CcSEcCtD
Gadoversetamide—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00852	0.00852	CcSEcCtD
Gadoversetamide—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.0081	0.0081	CcSEcCtD
Gadoversetamide—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.00806	0.00806	CcSEcCtD
Gadoversetamide—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00788	0.00788	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00783	0.00783	CcSEcCtD
Gadoversetamide—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.00779	0.00779	CcSEcCtD
Gadoversetamide—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.00776	0.00776	CcSEcCtD
Gadoversetamide—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00761	0.00761	CcSEcCtD
Gadoversetamide—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00756	0.00756	CcSEcCtD
Gadoversetamide—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00745	0.00745	CcSEcCtD
Gadoversetamide—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.00742	0.00742	CcSEcCtD
Gadoversetamide—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00741	0.00741	CcSEcCtD
Gadoversetamide—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00734	0.00734	CcSEcCtD
Gadoversetamide—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00727	0.00727	CcSEcCtD
Gadoversetamide—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.00713	0.00713	CcSEcCtD
Gadoversetamide—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00708	0.00708	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00702	0.00702	CcSEcCtD
Gadoversetamide—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.00695	0.00695	CcSEcCtD
Gadoversetamide—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.00682	0.00682	CcSEcCtD
Gadoversetamide—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.00679	0.00679	CcSEcCtD
Gadoversetamide—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.0066	0.0066	CcSEcCtD
Gadoversetamide—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.00655	0.00655	CcSEcCtD
Gadoversetamide—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00653	0.00653	CcSEcCtD
Gadoversetamide—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00644	0.00644	CcSEcCtD
Gadoversetamide—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00644	0.00644	CcSEcCtD
Gadoversetamide—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00644	0.00644	CcSEcCtD
Gadoversetamide—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00642	0.00642	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00639	0.00639	CcSEcCtD
Gadoversetamide—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00636	0.00636	CcSEcCtD
Gadoversetamide—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.0063	0.0063	CcSEcCtD
Gadoversetamide—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00622	0.00622	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.00617	0.00617	CcSEcCtD
Gadoversetamide—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.00617	0.00617	CcSEcCtD
Gadoversetamide—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00605	0.00605	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00604	0.00604	CcSEcCtD
Gadoversetamide—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00599	0.00599	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.00597	0.00597	CcSEcCtD
Gadoversetamide—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.00588	0.00588	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00562	0.00562	CcSEcCtD
Gadoversetamide—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00558	0.00558	CcSEcCtD
Gadoversetamide—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00554	0.00554	CcSEcCtD
Gadoversetamide—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.0055	0.0055	CcSEcCtD
Gadoversetamide—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00549	0.00549	CcSEcCtD
Gadoversetamide—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.00543	0.00543	CcSEcCtD
Gadoversetamide—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00537	0.00537	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00533	0.00533	CcSEcCtD
Gadoversetamide—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00532	0.00532	CcSEcCtD
Gadoversetamide—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.00528	0.00528	CcSEcCtD
Gadoversetamide—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.00528	0.00528	CcSEcCtD
Gadoversetamide—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00509	0.00509	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00505	0.00505	CcSEcCtD
Gadoversetamide—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.0049	0.0049	CcSEcCtD
Gadoversetamide—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00488	0.00488	CcSEcCtD
Gadoversetamide—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00488	0.00488	CcSEcCtD
Gadoversetamide—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00455	0.00455	CcSEcCtD
Gadoversetamide—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00443	0.00443	CcSEcCtD
Gadoversetamide—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00437	0.00437	CcSEcCtD
Gadoversetamide—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00422	0.00422	CcSEcCtD
Gadoversetamide—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00408	0.00408	CcSEcCtD
Gadoversetamide—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.00392	0.00392	CcSEcCtD
Gadoversetamide—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00389	0.00389	CcSEcCtD
Gadoversetamide—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00389	0.00389	CcSEcCtD
Gadoversetamide—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00387	0.00387	CcSEcCtD
Gadoversetamide—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00367	0.00367	CcSEcCtD
